How much did regional sales contribute to dupixent's q4 2020 revenue?

Dupixent (dupilumab) – Q4 2020

| Region | Net sales (US $) | % of Q4 2020 total |
|--------|------------------|--------------------|
| North America | ≈ 1.25 billion | ~72 % |
| Rest of the World | ≈ 0.49 billion | ~28 % |
| Total | ≈ 1.74 billion | – |

So, regional (North American) sales made up roughly $1.25 billion of Dupixent’s total Q4 2020 revenue, which represents about 72 % of the drug’s overall sales that quarter.

Source: Regeneron Pharmaceuticals’ Q4 2020 earnings release (Net sales figures for Dupixent).